Recombinant Anti-SET/TAF-I antibody [EPR12972(B)] (ab176567)


  • Product name

    Anti-SET/TAF-I antibody [EPR12972(B)]
    See all SET/TAF-I primary antibodies
  • Description

    Rabbit monoclonal [EPR12972(B)] to SET/TAF-I
  • Host species

  • Tested applications

    Suitable for: IP, Flow Cyt, WBmore details
    Unsuitable for: ICC/IF or IHC-P
  • Species reactivity

    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide within Human SET/TAF-I aa 1-100 (Cysteine residue). The exact sequence is proprietary.
    Database link: Q01105

  • Positive control

    • Jurkat, 293T, HepG2 and HeLa whole cell lysate (ab150035); Jurkat cells.
  • General notes

     This product was previously labelled as SET


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab176567 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IP 1/10 - 1/100.
Flow Cyt 1/10 - 1/100.

ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.


WB 1/10000 - 1/50000. Predicted molecular weight: 33 kDa.
  • Application notes
    Is unsuitable for ICC/IF or IHC-P.
  • Target

    • Function

      Multitasking protein, involved in apoptosis, transcription, nucleosome assembly and histone binding. Isoform 2 anti-apoptotic activity is mediated by inhibition of the GZMA-activated DNase, NME1. In the course of cytotoxic T-lymphocyte (CTL)-induced apoptosis, GZMA cleaves SET, disrupting its binding to NME1 and releasing NME1 inhibition. Isoform 1 and isoform 2 are potent inhibitors of protein phosphatase 2A. Isoform 1 and isoform 2 inhibit EP300/CREBBP and PCAF-mediated acetylation of histones (HAT) and nucleosomes, most probably by masking the accessibility of lysines of histones to the acetylases. The predominant target for inhibition is histone H4. HAT inhibition leads to silencing of HAT-dependent transcription and prevents active demethylation of DNA. Both isoforms stimulate DNA replication of the adenovirus genome complexed with viral core proteins; however, isoform 2 specific activity is higher.
    • Tissue specificity

      Widely expressed. Low levels in quiescent cells during serum starvation, contact inhibition or differentiation. Highly expressed in Wilms' tumor.
    • Involvement in disease

      Note=A chromosomal aberration involving SET is found in some cases of acute undifferentiated leukemia (AUL). Translocation t(6;9)(q21;q34.1) with NUP214/CAN.
    • Sequence similarities

      Belongs to the nucleosome assembly protein (NAP) family.
    • Domain

      The C-terminal acidic domain mediates the inhibition of histone acetyltransferases and is required for the DNA replication stimulatory activity.
    • Post-translational

      Isoform 2 is phosphorylated on Ser-15 and Thr-23.
      Isoform 2 is acetylated on Lys-11.
      Some glutamate residues are glycylated by TTLL8. This modification occurs exclusively on glutamate residues and results in a glycine chain on the gamma-carboxyl group.
      N-terminus of isoform 1 is methylated by METTL11A/NTM1. Mainly trimethylated.
    • Cellular localization

      Cytoplasm > cytosol. Endoplasmic reticulum. Nucleus > nucleoplasm. In the cytoplasm, found both in the cytosol and associated with the endoplasmic reticulum. Following CTL attack, moves rapidly to the nucleus, where it is found in the nucleoplasm, avoiding the nucleolus. Similar translocation to the nucleus is also observed for lymphocyte-activated killer cells after the addition of calcium. The SET complex is associated with the endoplasmic reticulum.
    • Information by UniProt
    • Database links

    • Alternative names

      • 2PP2A antibody
      • HLA DR associated protein II antibody
      • HLA-DR-associated protein II antibody
      • I 2PP2A antibody
      • I-2PP2A antibody
      • I2PP2A antibody
      • IGAAD antibody
      • Inhibitor of granzyme A activated DNase antibody
      • Inhibitor of granzyme A-activated DNase antibody
      • Inhibitor of GzmA-activated DNase antibody
      • inhibitor-2 of protein phosphatase-2A antibody
      • IPP2A2 antibody
      • PHAPII antibody
      • Phosphatase 2A inhibitor I2PP2A antibody
      • protein phosphatase type 2A inhibitor antibody
      • Protein SET antibody
      • Set antibody
      • SET nuclear oncogene antibody
      • SET translocation antibody
      • SET translocation (myeloid leukemia-associated) antibody
      • SET_HUMAN antibody
      • TAF I antibody
      • TAF IBETA antibody
      • TAF-I antibody
      • TAFI antibody
      • Template activating factor I antibody
      • Template-activating factor I antibody
      • Template-Activating Factor-I, chromatin remodelling factor antibody
      see all


    • All lanes : Anti-SET/TAF-I antibody [EPR12972(B)] (ab176567) at 1/10000 dilution

      Lane 1 : Jurkat cell lysate
      Lane 2 : 293T cell lysate
      Lane 3 : HepG2 cell lysate
      Lane 4 : HeLa cell lysate

      Lysates/proteins at 10 µg per lane.

      All lanes : Goat anti-rabbit HRP at 1/2000 dilution

      Developed using the ECL technique.

      Predicted band size: 33 kDa

    • Flow cytometry analysis of permeabilized Jurkat cells labeling SET/TAF-I (red) with ab176567 at a 1/10 dilution, or negative control rabbit IgG (green)

    • Western blot analysis on immunoprecipitation pellet from HeLa cell lysate labeling SET/TAF-I with ab176567 at 1/10 dilution.


    ab176567 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab176567.
    Please use the links above to contact us or submit feedback about this product.

    For licensing inquiries, please contact

    Sign up